Santaris Pharma A/S and Shire have extended their existing partnership for the development of therapies for rare genetic diseases. Shire will have the right to select additional targets for drug discovery and development. Santaris will receive an upfront payment and is eligible for research support, preclinical, clinical and sales milestones, as well as royalties on any products resulting from the collaboration.   Henrik Stage, president and chief executive officer at Santaris Pharma, said, &#82...